Biogen Idec Receives Fast Track Designation From FDA For PEGylated Interferon Beta-1a For Relapsing Multiple Sclerosis
Links shared publicly online about this topic.
- 1,910total visits
Biogen Idec Receives Fast Track Designation From FDA For PEGylated Interferon Beta-1a For Relapsing Multiple Sclerosis
Biogen Idec (NASDAQ: BIIB) announced the U.S. Food and Drug Administration (FDA) has granted PEGylated interferon beta-1a (BIIB017) Fast Track designation for relapsing multiple sclerosis (RMS).
View full resource at medicalnewstoday.com
Tags: Multiple Sclerosis, Multiple Sclerosis Medication, Drug, FDA, Avonex, Rebif, PEGylated interferon beta-1a, Biogen Idec
Most Recently Shared on July 9, 2009 at 5:14 pm By:
MedNewsToday: Biogen Idec Receives Fast Track Designation From FDA For PEGylated Interferon Beta-1a.. http://twurl.nl/vwqmdp
Advertisement
